Top

Breast Cancer Research and Treatment

Published in:

01-07-2014 | Rebuttal Letter

Determining axillary concordance rate for different injection locations in sentinel node mapping of breast cancer: how ambitious can we get?

Authors: Ramin Sadeghi, Mehdi Asadi, Giorgio Treglia, Seyed Rasoul Zakavi, Asiehsadat Fattahi, David N. Krag

Published in: Breast Cancer Research and Treatment | Issue 1/2014

Excerpt

To the Editor, …

Sadeghi R, Asadi M, Treglia G et al (2014) Axillary concordance between superficial and deep sentinel node mapping material injections in breast cancer patients: systematic review and meta-analysis of the literature. Breast Cancer Res Treat 144(2):213–222. doi:10.1007/s10549-014-2866-1 PubMedCrossRef

Asadi M, Shobeiri H, Aliakbarian M et al (2013) Reproducibility of lymphoscintigraphy before and after excisional biopsy of primary breast lesions: a study using superficial peri-areolar injection of the radiotracer. Rev Esp Med Nucl Imag Mol 32(3):152–155. doi:10.1016/j.remn.2012.07.004

Sadeghi R, Forghani MN, Memar B et al (2009) Comparison of pre-operative lymphoscintigraphy with inter-operative gamma probe and dye technique regarding the number of detected sentinel lymph nodes. Hell J Nucl Med 12(1):30–32PubMed

Mehrabibahar M, Azizi S, Jangjoo A et al (2014) Concordance between peri-areolar blue dye and peri-incisional radiotracer injections for sentinel node mapping in patients with a history of primary breast cancer excisonal biopsy. Acta Chir Belg 114(1):31–33PubMed

Fowler JC, Solanki CK, Guenther I et al (2009) A pilot study of dual-isotope lymphoscintigraphy for breast sentinel node biopsy comparing intradermal and intraparenchymal injection. Eur J Surg Oncol 35(10):1041–1047. doi:10.1016/j.ejso.2009.02.018 PubMedCrossRef

Anan K, Mitsuyama S, Kuga H et al (2006) Double mapping with subareolar blue dye and peritumoral green dye injections decreases the false-negative rate of dye-only sentinel node biopsy for early breast cancer: 2-site injection is more accurate than 1-site injection. Surgery 139(5):624–629. doi:10.1016/j.surg.2005.11.007 PubMedCrossRef

Title: Determining axillary concordance rate for different injection locations in sentinel node mapping of breast cancer: how ambitious can we get?
Authors: Ramin Sadeghi
Mehdi Asadi
Giorgio Treglia
Seyed Rasoul Zakavi
Asiehsadat Fattahi
David N. Krag
Publication date: 01-07-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-2938-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2014

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients

HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer

Body mass index, diabetes, and triple-negative breast cancer prognosis

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster

Keynote webinar | Spotlight on antibody–drug conjugates in cancer